SCHEMBL10130338

SCHEMBL10130338

Cc1cc(Cl)c2c(c1)NC(=O)C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 3/20 0.44
CMA1 P23946 2/20 0.44
RIPK1 Q13546 1/20 0.40
GSK3B P49841 7/20 0.38
CCNB2 O95067 5/20 0.38
CDK1 P06493 5/20 0.38
CCNB1 P14635 5/20 0.38
CCNB3 Q8WWL7 5/20 0.38
CDK5 Q00535 5/20 0.38
CDK5R1 Q15078 5/20 0.38
MMP12 P39900 1/20 0.38
GRIA1 P42261 1/20 0.37
CACNG8 Q8WXS5 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PDE7A Q13946 1/20 0.36
EPHX2 P34913 1/20 0.35
GSK3A P49840 2/20 0.35
MAPT P10636 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5378136 0.81 CA12 (0.40) AHRCMA1GSK3BCCNB2CDK1
SCHEMBL5789814 0.78 GSK3B (0.38) AHRCMA1GSK3BCCNB2CDK1
SCHEMBL31383739 0.78 CMA1 (0.41) AHRCMA1GSK3BCCNB2CDK1
SCHEMBL5246021 0.78 CMA1 (0.41) AHRCMA1GSK3BCCNB2CDK1
SCHEMBL496039 0.78 AHR (0.44) AHRCMA1RIPK1GSK3BCCNB2
SCHEMBL23408301 0.77 AHR (0.41) AHRCMA1RIPK1GSK3BCCNB2
SCHEMBL9701376 0.77 PDE7A (0.34) PDE7A
SCHEMBL10129810 0.74 POLB (0.37) GSK3BCCNB2CDK1CCNB1CCNB3
SCHEMBL5789641 0.73 GPR35 (0.44) GSK3BCCNB2CDK1CCNB1CCNB3
SCHEMBL20278370 0.71 PDE3B (0.55) MMP12MAPTPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 AHR 472/4885CMA1 970/4885RIPK1 4492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.